These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 25220191)

  • 1. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
    Eng C; Kramer CK; Zinman B; Retnakaran R
    Lancet; 2014 Dec; 384(9961):2228-34. PubMed ID: 25220191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
    Nauck MA; Mirna AEA; Quast DR
    Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Tran S; Retnakaran R; Zinman B; Kramer CK
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Maiorino MI; Chiodini P; Bellastella G; Capuano A; Esposito K; Giugliano D
    Diabetes Care; 2017 Apr; 40(4):614-624. PubMed ID: 28325801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.
    Liakopoulou P; Liakos A; Vasilakou D; Athanasiadou E; Bekiari E; Kazakos K; Tsapas A
    Endocrine; 2017 Jun; 56(3):485-494. PubMed ID: 28401444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
    Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
    Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
    Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Maiorino MI; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Esposito K; Giugliano D
    Diabetes Obes Metab; 2018 Sep; 20(9):2309-2313. PubMed ID: 29732679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials.
    Maiorino MI; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Giugliano D; Esposito K
    Diabetes Res Clin Pract; 2019 Aug; 154():101-115. PubMed ID: 31238059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
    Carris NW; Taylor JR; Gums JG
    Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDegLira for type 2 diabetes: a systematic review and meta-analysis.
    Liu Y; Li X; Zheng Y; Wang X; Wang X
    Endocrine; 2024 Mar; 83(3):648-658. PubMed ID: 37768513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
    Mehta R; Billings LK; Liebl A; Vilsbøll T
    Diabet Med; 2022 Sep; 39(9):e14901. PubMed ID: 35708737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
    Wilding JP; Bain SC
    Diabet Med; 2016 Jul; 33(7):864-76. PubMed ID: 26525806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.
    Liu SC; Tu YK; Chien MN; Chien KL
    Diabetes Obes Metab; 2012 Sep; 14(9):810-20. PubMed ID: 22486990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
    Raccah D; Gourdy P; Sagnard L; Ceriello A
    Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.